Jun 16 2010
VIVUS, Inc. (Nasdaq: VVUS) today announced that data on Qnexa®, an investigational drug candidate, will be presented at the Endocrine Society's 92nd Annual Meeting and Expo (ENDO) in San Diego, California. Timothy Garvey, M.D., professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham and a Qnexa investigator, will deliver an oral presentation at the Clinical Trials Symposium on Saturday, June 19, entitled: "Once-Daily, Low-Dose, Controlled-Release Phentermine/Topiramate Demonstrates Significant Improvement in Weight, Related Risk in Overweight/Obese Patients with Comorbidities."
"We are pleased to have a significant presence at this year's ENDO meeting, where Dr. Timothy Garvey will present data that further illustrate the potential impact that Qnexa, if approved, may have on life-threatening weight-related comorbidities, including cholesterol, blood pressure and diabetes," stated Wesley Day, PhD, vice president, clinical development at VIVUS. "We look forward to sharing these important data with our colleagues in the endocrinology community."
Following are details about the upcoming presentation:
The Endocrine Society's 92nd Annual Meeting and Expo, San Diego, Calif.
Date and Time: Saturday, June 19, 2010, 3:45-4 PM PDT
Session: Clinical Trials Symposium
Abstract: S19-5
Presentation Title: Once-Daily, Low-Dose, Controlled-Release Phentermine/Topiramate Demonstrates Significant Improvement in Weight, Related Risk in Overweight/Obese Patients with Comorbidities
Location: Room 29ABC, San Diego Convention Center
Presenter: W. Timothy Garvey, M.D.
SOURCE VIVUS, Inc.
How nutrition and telomere dynamics shape beauty and aging in women